Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma

NCT05157763 is registered in ClinicalTrials.gov with MediWound Ltd as lead sponsor.

NCT NCT05157763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05157763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma
Lead sponsor
MediWound Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 30, 2021
Completion date
June 30, 2022
Enrollment
32 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

nodular basal cell carcinoma, superficial basal cell carcinoma